Not medical advice. Talk to your provider before using any peptide.
Full disclaimer
GLOW Blend (BPC-157 + TB-500 + GHK-Cu)25 residues (approx.)GEPPPGKPADDAGLVLKKTETQGHKEach bubble = one amino acid. Size = residue mass. Color = chemical class.Uses closest standard amino acids for non-standard residues.Also known as: GLOW Stack, Triple Healing Stack, Wolverine Stack Plus
Three peptides, three repair pathways, one syringe. The GLOW Blend pairs BPC-157 and TB-500 (the original Wolverine Stack) with GHK-Cu, a copper-binding tripeptide that activates over 4,000 human genes tied to tissue regeneration (Pickart)[1]. Community users report smoother skin texture and faster injury recovery within three to six weeks. Zero combination trials exist in humans, and all clinical evidence comes from preclinical animal models or tiny pilot studies. Athletes recovering from soft tissue injuries and people chasing collagen density are the primary audience for this stack.
Over 4,000 human genes respond to a single copper-binding tripeptide. That tripeptide is GHK-Cu, and the GLOW Blend builds an entire healing protocol around it. Full name: BPC-157 + TB-500 + GHK-Cu (also called the triple healing stack). No CAS number exists for the combination. BPC-157 upregulates VEGF to build new blood vessels at injury sites. It modulates nitric oxide for vascular protection and activates the FAK-paxillin pathway for tendon and ligament repair. TB-500 (the active fragment of Thymosin Beta-4) upregulates actin, a cell-building protein that moves repair cells to wound sites. It also drops pro-inflammatory cytokines across the entire body. GHK-Cu delivers copper ions to tissue, triggering collagen I and III synthesis and decorin expression for organized (not fibrotic) tissue remodeling. Community adoption sits at roughly 200+ Reddit threads and a 4.3/5 sentiment score. Users consistently describe higher-quality healed tissue compared to BPC-157 plus TB-500 alone, with less scar formation and visible skin improvements by week four. The primary complaint: budget pre-mixed vials deliver roughly 200 mcg of GHK-Cu, which is 5 to 10 times below the community-effective dose of 1 to 2 mg daily. The honest assessment: zero human combination trials exist. BPC-157 has one published human pilot (n=2, IV only)[2]. TB-500 has no human data at all for the subcutaneous route; the Phase I PK often cited (PMC8419156) studied recombinant full-length thymosin beta-4 given IV. GHK-Cu evidence is primarily in vitro and animal. Promising preclinical data and strong community consensus, but the clinical gap is real.
The GLOW Blend works through three distinct repair pathways that don't overlap. BPC-157 handles local, targeted repair. It upregulates vascular endothelial growth factor (VEGF) to drive angiogenesis at the injury site. New blood vessel formation accelerates nutrient delivery to damaged tissue. BPC-157 also modulates nitric oxide signaling for vascular protection and activates the FAK-paxillin pathway, which is specific to tendon and ligament fibroblast repair [3]. TB-500 works systemically. As the active fragment of Thymosin Beta-4, it upregulates actin, a protein that enables cell migration and proliferation at wound sites. Preclinical wound studies showed 42 to 61% increases in reepithelialization versus controls. TB-500 simultaneously reduces pro-inflammatory cytokines body-wide [4]. The plasma half-life usually cited for it, 0.5 to 2.08 hours, comes from a Phase I study of recombinant full-length thymosin beta-4 given intravenously (PMC8419156). That is a different molecule by a different route. No human dose-finding or PK data exists for subcutaneous TB-500. GHK-Cu adds the structural remodeling layer. This copper-binding tripeptide delivers copper ions directly to tissue, activating collagen I and III synthesis and promoting decorin expression. Decorin matters because it organizes collagen fibers into functional architecture rather than disorganized scar tissue. Pickart's group mapped over 4,000 human genes modulated by GHK-Cu in skin regeneration contexts [1]. Separate work confirmed GHK-Cu regulates antioxidant gene expression [5]. The three peptides clear plasma within hours. Structural and gene expression effects persist for weeks after clearance.
No combination studies exist for the three-peptide blend. Individual components have preclinical (animal) support. BPC-157 has one published human IV safety pilot (n=2, 2025)[2]. TB-500 has no human data for the subcutaneous route; the Phase I PK cited for it (PMC8419156) studied recombinant full-length thymosin beta-4 given IV. GHK-Cu has gene-modulation in vitro data [1]. No RCTs for any component in the healing indications claimed.
PMID 40131143 (2025 BPC-157 IV pilot, n=2, no adverse effects on cardiac/hepatic/renal/thyroid biomarkers); PMC12313605 (2025 systematic review BPC-157 orthopaedic sports medicine); PMID 29986520 (GHK-Cu modulates 4,000+ human genes in skin regeneration, 2015); PMC8419156 (Phase I human PK of recombinant full-length thymosin beta-4 given IV, plasma t½ 0.5–2.08 hours: a different molecule and route from subcutaneous TB-500, for which no human dose-finding data exists)
Zero human combination trials. BPC-157 pilot is n=2, uncontrolled, IV only (not SC). TB-500 human data is PK only: no efficacy endpoints. GHK-Cu data is primarily in vitro and animal. No dose-finding, safety, or efficacy RCTs for any component in humans.
Positive sentiment; users report meaningful healing quality improvement vs. BPC-157 + TB-500 alone, attributing collagen and skin/connective tissue benefits to GHK-Cu. Primary concern: GHK-Cu underdosing in budget pre-mixed vials undermines outcomes.
Individual component science is weak-to-moderate (preclinical dominant; one tiny human pilot for BPC-157). Community use is enthusiastic and broadly positive, but the combination ratios and cycle structures are entirely community-designed. Key divergence: TB-500 community-preferred dosing (2×/week SC) conflicts with daily pre-mixed vial formats sold commercially.
This blend is run in more than one way. The dosing table below describes the pre-blended 70 mg vial only.
The ratio is fixed by the vendor. You cannot move one component without moving all three. Raising the blend dose raises GHK-Cu with it.
Community cycles run 4 to 8 weeks with a 2-week minimum break. The originating protocol sets no fixed length: it says to run until healing is achieved and take at least 15 days off between cycles. Neither schedule has trial support.
Two sources conflict and neither is authoritative. The originating protocol says to hold the 5:1:1 ratio when dosing separately. Community separate-vial reports use GHK-Cu 2 mg per day, BPC-157 500 mcg per day, and TB-500 2 mg twice weekly, which is not 5:1:1. Both are presented here; pick with a prescriber.
Community cycles run 4 to 8 weeks with a 2-week minimum break.
GHK-Cu sets the tier (1 to 2 mg per day, subcutaneous). Community consensus. No human trial establishes an injectable GHK-Cu dose at any level.
GHK-Cu is 50 mg of the 70 mg vial, so it is 71 percent of every draw. The GHK-Cu dose sets the tier and the total follows from the ratio. 1,000 mcg GHK-Cu needs a 1,400 mcg draw. 1,670 mcg needs 2,330 mcg, the amount the originating protocol describes. 2,000 mcg needs 2,800 mcg.
Vendor ratios are not standardized. Confirm the milligram breakdown on your COA before dosing. If your ratio differs, the component split above does not apply. Budget vials have been reported at roughly 200 mcg GHK-Cu per dose, 5 to 10 times below the community range.
| Level | Dose / Injection | Frequency |
|---|---|---|
| Beginner | 1.4mg | Daily |
| Moderate | 2.33mgMatches the dose the originating protocol describes: about 1,670 mcg GHK-Cu per injection. | Daily |
| Aggressive | 2.8mgTop of the 1 to 2 mg per day community range for GHK-Cu. No source establishes a higher blend dose. | Daily |
Your first decision with this stack is vial format. Pre-mixed 70mg vials (typically 50mg GHK-Cu, 10mg BPC-157, 10mg TB-500) simplify everything into one daily draw. Separate component vials cost more time but let you dose TB-500 twice weekly (the community-preferred frequency) and avoid copper-catalyzed oxidation in a shared solution. Reconstitution math for the 70mg vial with 3 mL bacteriostatic water: concentration is 23.3 mg/mL, so one unit on a U-100 insulin syringe holds about 233 mcg. The beginner tier of 1,400 mcg is 6 units. Moderate (2,330 mcg) is 10 units. Aggressive (2,800 mcg) is 12 units. Do not carry over syringe unit calculations between vial formats. The thing most beginners miss: budget pre-mixed vials may contain only 200 mcg of GHK-Cu per dose. That is 5 to 10 times below the effective community dose. Check the vendor COA for exact component milligram breakdown before buying.
Community cycles run 4 to 8 weeks depending on injury severity, 6 weeks most often, with a 2-week minimum break. The originating GLOW protocol sets no fixed length: it says to run until healing is achieved and take at least 15 days off between cycles. Neither schedule has trial support. For acute injuries 4 to 6 weeks is typical; some users extend to 8 weeks for chronic conditions with provider oversight.
No long-term combination safety data exists. Cycling limits cumulative copper load from GHK-Cu component and allows assessment of treatment response and adverse effects. GHK-Cu copper delivery is the primary driver: extended continuous use risks hepatic copper accumulation. The 4–8 week active / 2-week minimum off cycle is community consensus with no clinical trial basis for this specific combination. Receptor desensitization is sometimes given as the reason to cycle this stack. No desensitization data exists for BPC-157, TB-500, or GHK-Cu. The documented tachyphylaxis belongs to GH secretagogues, which are a different class and are not in this blend. Safety monitoring is the defensible reason to cycle; desensitization is not.
Or use the universal Peptide Calculator for any peptide.
One page: what is in the vial, the dose each tier delivers per component, syringe units, cycling, and where every number comes from.
Expected: Community reports describe reduced injury-site inflammation by week 2 and skin texture change by week 3 to 4. No trial measures any endpoint for this combination.
Monitor: Baseline serum copper and ceruloplasmin, repeated mid-cycle. Wilson's disease or copper metabolism disorder: absolute contraindication. WADA athletes: BPC-157 and TB-500 are both prohibited.
Gather supplies: reconstituted GLOW vial (or separate component vials), alcohol swabs, 29 or 31 gauge insulin syringe (U-100, 0.5 mL or 1 mL), and a sharps container.
Draw the calculated dose. For the pre-blended 70mg vial in 3 mL bac water (23.3 mg/mL): beginner 1,400 mcg = 6 units; moderate 2,330 mcg = 10 units; aggressive 2,800 mcg = 12 units.
If you bought three component vials instead of a pre-blended one, draw each peptide into a separate syringe. These numbers do not apply to the pre-blended vial in step 2. BPC-157 and TB-500 assume 10mg vials in 2 mL bac water (5 mg/mL): BPC-157 500 mcg = 10 units, TB-500 2 mg = 40 units (twice weekly only, not daily). GHK-Cu assumes the 50mg vial in 5 mL bac water (10 mg/mL) the GHK-Cu page uses: 2 mg = 20 units.
For targeted injury repair, inject subcutaneously near the injury. For general healing and systemic recovery, use abdominal subcutaneous injection. Rotate sites every 2 inches from the navel.
Pinch a fold of skin, insert the needle at a 45-degree angle, inject slowly, and withdraw. Apply light pressure with an alcohol swab.
Return the reconstituted vial to the refrigerator (2 to 8 degrees Celsius). Use within three to four weeks. Never freeze reconstituted solution.
Reference dose
Abdominal SC preferred; rotate sites every 2 inches from navel. Near-injury injection may enhance local BPC-157 effects for targeted repair.
Same dose; potentially faster peak absorption but increased discomfort
No clinical evidence of meaningful difference vs SC for peptide bioavailability. IM adds injection discomfort without clear benefit for subcutaneous peptides.
Topical GHK-Cu serum (~$30–80/month) can augment injectable protocol for aesthetic goals without replacing injectable dosing
Topical GHK-Cu has documented skin penetration data and is commercially available as a skincare ingredient. BPC-157 and TB-500 topical bioavailability is negligible: these require injection.
BPC-157 oral dose typically 1–5 mg (higher than SC 250–500 mcg) to account for GI degradation
For GI-specific BPC-157 applications, oral route is separately used. Not applicable to the full GLOW three-peptide stack: TB-500 and GHK-Cu require injection.
GH pulse supports anabolic healing environment; community adds this for advanced tissue repair and body composition
100–200 mcg 2–3×/day alongside GLOW protocol, pre-sleep or fasted
Paired with Ipamorelin for amplified pulsatile GH release; supports growth factor environment for tissue repair
100–200 mcg with each Ipamorelin injection
Fourth component in the KLOW Blend variant; adds anti-inflammatory NF-κB inhibition, particularly useful for GI healing alongside GLOW
500 mcg–1 mg/day oral or SC
Topical GHK-Cu serum (0.1–1%) augments injectable protocol for facial and dermal application when aesthetic goals are primary
Topical 0.1–1% serum applied to target skin areas; ~$30–80/month
GHK-Cu delivers systemic copper; concurrent copper supplementation risks copper overload, particularly during extended cycles >6 weeks
TB-500 may affect clotting pathways; BPC-157 pro-angiogenic effects. Combination with anticoagulants is unstudied; theoretical bleeding risk amplification
BPC-157 promotes angiogenesis via VEGFR2: directly antagonizes anti-angiogenic cancer treatments and theoretically feeds tumor vasculature
Do not combineTB-500 modulates immune response; interaction with calcineurin inhibitors is unstudied and theoretically unpredictable
Pricing updated 2026-04-09
BPC-157 promotes angiogenesis via VEGFR2. That is the most serious safety concern in this stack. Anyone with active cancer or a history of cancer should not use GLOW. New blood vessel formation can theoretically feed tumor vasculature, and this risk is not theoretical enough to dismiss. BPC-157 directly antagonizes anti-angiogenic cancer therapies. GHK-Cu delivers exogenous copper systemically. Copper excess accumulates in the liver. Early signs include metallic taste, nausea, and abdominal discomfort. Users with Wilson's disease or any copper metabolism disorder have an absolute contraindication to this stack. Serum copper and ceruloplasmin testing at baseline is recommended, with repeat testing at week six for extended cycles or GHK-Cu doses above 2 mg daily. Target ranges: serum copper 70 to 140 mcg/dL, ceruloplasmin 20 to 40 mg/dL. TB-500 may affect clotting pathways. The interaction with anticoagulants (warfarin, heparin, DOACs) is unstudied in humans; theoretical bleeding risk exists. Unusual bruising or bleeding warrants immediate discontinuation. Injection site reactions are common across all three components. Redness, mild swelling, and irritation usually resolve within hours. GHK-Cu has a visible blue-teal tint from copper chelation. Mild discoloration at the injection site is normal and clears within 24 hours. Persistent swelling or redness points to insufficient site rotation. Community-reported side effects during week one include mild headache, occasional nausea, and lightheadedness. GHK-Cu may cause skin flushing on the first injection at higher doses. These typically resolve by week three. Human safety data is extremely limited. BPC-157 has one published pilot with two participants (IV route only)[2]. TB-500 human data covers pharmacokinetics only. GHK-Cu evidence is primarily in vitro and animal. The total number of humans formally studied on any component in this stack is under 50. When to stop: persistent headache lasting more than 48 hours; metallic taste or nausea that doesn't resolve; unusual bruising or bleeding; signs of infection at the injection site; any active cancer diagnosis. When to see a doctor: copper excess symptoms, allergic reaction (hives or difficulty breathing), or any effect that feels wrong. Pregnancy and breastfeeding: do not use. No reproductive safety data exists for any component.
No results by week 3: Verify GHK-Cu is adequately dosed. Budget pre-mixed vials may contain ~200 mcg GHK-Cu vs. the effective community dose of 1–2 mg. Check vendor COA for exact component mg breakdown; switch to separate vials if unverifiable.
Injection site turns bluish: GHK-Cu has a visible blue/teal tint due to copper chelation: mild discoloration at the injection site is normal and resolves within 24 hours. Persistent swelling or redness indicates insufficient site rotation.
Metallic taste or nausea after injection: Early indicator of copper sensitivity or mild copper excess from GHK-Cu. Reduce GHK-Cu dose by 50% for one week; discontinue if symptoms persist >48 hours.
No TB-500 effect: If using a pre-mixed daily vial, TB-500 is delivered in small daily fractions rather than the community-preferred 2×/week dosing. TB-500 tissue effects are dose-pulse–dependent in preclinical models: switch to separate vials for proper twice-weekly schedule.
Your vial ratio does not match 50/10/10: vendor ratios are not standardized, and other splits are sold. The total mcg your calculator shows is still correct for any vial size you enter, but the per-component split on this page assumes 5:1:1 and will be wrong for a vial built to a different ratio. Read the COA, then work out the split from the milligram breakdown printed on it.
Verify GLOW Blend (BPC-157 + TB-500 + GHK-Cu) dosing and safety with a second opinion
Multi-peptide pre-mixed formulations present compounded stability risks: copper from GHK-Cu can catalyze oxidation of TB-500 (methionine oxidation susceptibility) and BPC-157 over time in solution. GHK-Cu component dosing in pre-mixed vials is highly variable and often undisclosed: market ranges from ~200 mcg (budget) to 50 mg (standard 70mg vial) per vial. No FDA oversight. Purity and ratio verification requires third-party COA.
| Test | When | Target |
|---|---|---|
| Serum copper / ceruloplasmin | Baseline before starting; repeat at week 6 for extended cycles or GHK-Cu doses >2 mg/day | Serum copper: 70–140 mcg/dL; ceruloplasmin: 20–40 mg/dL |
| Liver function panel (ALT, AST, bilirubin) | Baseline; repeat if metallic taste, nausea, or other copper excess signs emerge | — |
| CBC with differential | Baseline recommended for extended cycles (>8 weeks) | — |
| Cancer screening (age-appropriate) | Before starting, particularly for users >40 or with relevant family history | — |
GHK-Cu delivers exogenous copper systemically; monitor for copper accumulation, particularly with high GHK-Cu doses or pre-existing liver conditions
Copper excess can cause hepatic accumulation. Standard safety monitoring for any injectable protocol.
Copper at elevated levels affects hematopoiesis; BPC-157 modulates platelet function in animal models. Baseline establishes reference range.
BPC-157 promotes angiogenesis via VEGFR2: absolute contraindication if active cancer. Ensure no occult malignancy before starting.
Reduced inflammation and pain at injury sites. Initial healing response begins.
Noticeable improvement in mobility and tissue repair. Collagen remodeling from GHK-Cu becomes apparent.
Significant recovery milestones. Scar tissue softening. Many users report near-full recovery from moderate injuries. End of standard 6-week cycle: evaluate results.
Two-week break. Healing continues from accumulated effects. Assess whether another cycle is needed or transition to single-peptide maintenance.
Week 1 to 2, Inflammation Reduction: BPC-157 begins modulating nitric oxide signaling and VEGF expression within 24 to 72 hours in animal models. TB-500 reduces pro-inflammatory cytokines acutely. GHK-Cu starts activating antioxidant genes. Community users report improved sleep, reduced pain and swelling at injury sites, and early wound healing acceleration. Some notice gut comfort improvements within the first week. Expect mild injection site redness that resolves within hours, occasional headache during days one through three, and possible nausea if the GHK-Cu dose is high on the first injection. Week 3 to 4, Tissue Remodeling Begins: VEGF-driven angiogenesis supports new vessel formation. TB-500 actin upregulation drives cell migration, with preclinical wound studies showing 42 to 61% increases in reepithelialization versus controls. GHK-Cu collagen I and III synthesis ramps up. Community reports describe smoother skin texture, increased elasticity, and a visible "glow." Athletes report returning to training with reduced pain. Side effects are usually resolved by this point; occasional persistent injection site marking if rotation is insufficient. Week 5 to 8, Peak Healing and Collagen Density: GHK-Cu collagen remodeling favors organized architecture over fibrotic scar tissue through decorin expression. BPC-157 FAK-paxillin pathway effects on tendon repair mature at four to six weeks in preclinical models. Community users report scar tissue softening, fine line reduction, near-full recovery from moderate soft tissue injuries, and peak skin elasticity improvements. The "glow" effect is most pronounced during this window. Minimal side effects if cycling properly and copper dose stays reasonable. Post-Cycle Weeks 9 to 10, Sustained Effects: All three peptides clear plasma within hours, but structural effects driven by downstream gene expression persist. GHK-Cu gene modulation may outlast plasma presence. Community users report maintained elasticity and scar improvements four to eight weeks post-cycle. This is the assessment window: determine whether a second cycle is needed for chronic conditions or whether improvement continues without intervention.
BPC-157 modulates nitric oxide signaling and VEGF expression within 24–72 hours (animal models). TB-500 reduces pro-inflammatory cytokines acutely. GHK-Cu begins antioxidant gene activation.
Improved sleep, reduced pain and swelling at injury site, early wound healing acceleration, some report gut comfort improvement within first week.
VEGF-driven angiogenesis supports new vessel formation; TB-500 actin upregulation drives cell migration and reepithelialization (42–61% increase vs controls in preclinical wound studies). GHK-Cu collagen I/III synthesis upregulation ramps up.
Smoother skin texture, increased elasticity, visible "glow," improved mobility. Athletes report returning to training with reduced pain.
GHK-Cu collagen remodeling favors organized vs. fibrotic architecture (decorin expression). BPC-157 FAK-paxillin pathway effects on tendon repair mature at 4–6 weeks in preclinical models.
Scar tissue softening, fine line reduction, near-full recovery from moderate soft tissue injuries, peak skin elasticity improvements. Community-reported "glow" effect most pronounced.
Collagen remodeling continues after peptide clearance (all three peptides clear plasma within hours; structural effects driven by downstream gene expression persist). GHK-Cu gene modulation effects may outlast plasma presence.
Maintained elasticity and scar improvements reported 4–8 weeks post-cycle. Users assess whether second cycle is needed for chronic conditions vs. continued improvement.
Source: Estimated from primary component BPC-157 (~4h). The 0.5-2 hour plasma half-life often quoted for TB-500 comes from a Phase I study of recombinant full-length thymosin beta-4 given intravenously (PMC8419156), not the subcutaneous heptapeptide sold as TB-500. No human PK data exists for subcutaneous TB-500. GHK-Cu half-life is ~1 hour. Effective duration is driven by downstream biological activity, not plasma half-life.
BPC-157, TB-500, and GHK-Cu are sold as research compounds in the United States. None of the three components holds FDA approval for any therapeutic indication. The GLOW Blend combination has no regulatory status anywhere. These peptides are not approved drugs and are not legal for human therapeutic use outside of clinical research settings. BPC-157 and TB-500 are both explicitly prohibited by the World Anti-Doping Agency (WADA). Competitive athletes in any WADA-tested sport cannot use this stack. GHK-Cu is not currently on the WADA prohibited list. Compounding pharmacies in the US may prepare individual components under physician supervision. Physician-supervised clinical sessions (IV or injection) run $200 to $400 per treatment at peptide clinics. Research-grade pre-mixed vials are available from peptide vendors without prescription, though quality varies widely and no FDA oversight exists. This content is for educational and research purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. Consult a qualified healthcare provider before using any research peptide.
Peptide Schedule Research TeamReviewed Apr 202611 Citations
